Anticancer metallodrugs based on ruthenium and osmium are among the most investigated
and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has …

The clinical success of the platinum-based chemotherapeutic agents has prompted the
investigation of coordination and organometallic complexes of alternative metal centers for …

Countless expectations converge in the multidisciplinary endeavour for the search and
development of effective and safe drugs in fighting cancer. Although they still embody a …

Several reviews of inhibitors of topoisomerase II have been published, covering research
before 2018. Therefore, this review is focused primarily on more recent publications with …

(1) Background: Ruthenium and osmium complexes attract increasing interest as next
generation anticancer drugs. Focusing on structure-activity-relationships of this class of …

Various half-sandwich ruthenium (II) arene complexes and rhodium (III) arene complexes
have been intensively investigated due to their prominent anticancer activity. The interaction …

Platinum-based anticancer drugs are most likely the most successful group of bioinorganic
compounds. Their apparent disadvantages have led to the development of anticancer …

A series of five kinetically inert bis‐cyclometalated IrIII complexes of general formula [Ir (C^
N) 2 (N^ N)][PF6][C^ N= 2‐phenyl‐1‐[4‐(trifluoromethyl) benzyl]‐1H‐benzo [d] imidazol‐κN …

Colorectal cancer (CRC) is the third most common cancer globally, with high mortality.
Metastatic CRC is incurable in most cases, and multiple drug therapy can increase patients' …

Within this work we aimed to improve the pharmacodynamics and toxicity profile of
organoruthenium and-rhodium complexes which had previously been found to be highly …